2025年
論文原著
英 文
- Nagasaki S, Ishii K, Murakami Y, Tsutsui A, Hidaka N, Takahashi H, Ichizuka K, Miyakoshi K, Miura K, Miyashita S, Kamei Y, Nakata M; Study Group on New Reference Values for Fetal Biometry in Japan.
New reference values for ultrasound fetal biometry in Japanese population and comparison with other studies.
Sci Rep. 15(1): 30560, 2025 - Takeda E, Suzumori N, Samura O, Miura K, Kamei Y, Sawai H, Yamada T, Ichizuka K, Komatsu R, Wada S, Katagiri Y, Morisaki H, Nakayama S, Hamanoue H, Murotsuki J, Mimura K, Matsubara Y, Maeda K, Ida A, Ito M, Hayakawa H, Fujiwara A, Shirato N, Ishii T, Sago H, Sekizawa A.
Significance of noninvasive prenatal testing using massively parallel sequencing in women with twin or vanishing twin pregnancies.
J Hum Genet. 70(6): 297-305, 2025 - Akazawa Y, Yasukochi S, Takei K, Takigiku K, Inamura N, Takagi K, Pooh RK, Yoshimatsu J, Kamei Y, Tamaru S, Yamamoto Y, Miyake T, Hata T; Fetal HQ Study Group.
Normal values and distribution of ventricular global longitudinal strain in 513 healthy fetuses measured by two-dimensional speckle-tracking echocardiography: a multi-institutional cohort study.
Heart Vessels. 40(5): 414-425, 2025 - Yamamoto K, Suzumori N, Miura K, Yamada T, Kamei Y, Sawai H, Hamanoue H, Samura O, Wada S, Murotsuki J, Ichizuka K, Komatsu R, Katagiri Y, Morisaki H, Nakayama S, Mimura K, Matsubara Y, Okamoto Y, Maeda K, Yasuda S, Ida A, Ito M, Hayakawa H, Fujiwara A, Shirato N, Ishii T, Sago H, Sekizawa A.
Clinical Implications of Low Cell-Free DNA Fetal Fraction in Non-Invasive Prenatal Testing: A Retrospective Cohort Study of 40,716 Pregnancies.
Prenat Diagn. 45(12): 1572-1579, 2025 - Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
J Clin Oncol. 43(9): 1083-1100, 2025 - Oaknin A, Monk BJ, de Melo AC, Kim HS, Kim YM, Lisyanskaya AS, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin E, Takahashi S, Ramone D, Maćkowiak-Matejczyk B, Polastro L, Alia EMG, Colombo N, Makarova Y, Goh JC, Hasegawa K, Mora P, Pikiel J, Srivastav R, Rischin D, Rubio MJ, Perez J, Yoo SY, Gao B, Jamil S, Seebach F, Lowy I, Mathias M, Fury MG, Tewari KS.
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
Eur J Cancer. 216: 115146, 2025 - Cherifi F, Ray-Coquard I, Rubio MJ, Paoletti X, Lorusso D, Choi CH, Hasegawa K, Tan DSP, Hudson E, Davis A, Tognon G, Lheureux S, Vardar Key MA, Kurtz JE, Alexandre J, Joly F.
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.
Future Oncol. 21(13): 1613-1623, 2025 - Hasegawa K, Nishio S, Yamamoto K, Fujiwara H, Itagaki H, Nagai T, Takano H, Yamaguchi S, Kudoh A, Suzuki Y, Nakamoto T, Kurosaki A, Kamio M, Kato K, Nakamura K, Takehara K, Yahata H, Kobayashi H, Saito M, Fujiwara K.
Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial.
Eur J Cancer. 219: 115304, 2025 - Kim YM, Nishio S, Kim SI, Hasegawa K, Dubot C, Cáceres MV, Tewari KS, Lorusso D, Lee JW, Liou WS, Li K, Tekin C, Colombo N, Monk BJ.
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis.
J Gynecol Oncol. 36(4): e110, 2025 - Okazawa-Sakai M, Sakai SA, Hyodo I, Horasawa S, Sawada K, Fujisawa T, Yamamoto Y, Boku S, Hayasaki Y, Isobe M, Shintani D, Hasegawa K, Egawa-Takata T, Ito K, Ihira K, Watari H, Takehara K, Yagi H, Kato K, Chiyoda T, Harano K, Nakamura Y, Yamashita R, Yoshino T, Aoki D.
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.
J Gynecol Oncol. 36(3): e38, 2025 - Lee JY, Tan D, Ray-Coquard I, Lee JB, Kim BG, Van Nieuwenhuysen E, Huang RY, Tse KY, González-Martin A, Scott C, Hasegawa K, Wilkinson K, Yang EY, Lheureux S, Kristeleit R.
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80).
J Gynecol Oncol. 36(1): e51, 2025 - Tsuchimochi S, Yamamoto Y, Taguchi A, Kawazu M, Sone K, Ikemura M, Tamai K, Kitamura S, Yoshimoto D, Fukaya S, Ishizaka A, Quynh AD, Nishijima A, Miyamoto Y, Mori M, Hiraike O, Hasegawa K, Ushiku T, Oda K, Hirota Y, Osuga Y.
BRCA1 Promoter Methylation in Ovarian Cancer: Clinical Relevance and a Novel Diagnostic Approach Using Fragment Analysis.
Cancer Sci. 116(7): 1996-2007, 2025 - Eskander RN, Lee JY, Mirza MR, Lorusso D, MacKay H, Ray-Coquard I, Oaknin A, Gonzalez-Martin A, Hasegawa K, Corr BR, Wu X, Leary A, Hu T, Dutta L, Okpara CE, McKenzie J, Makker V.
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician’s choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors.
Int J Gynecol Cancer. 35(9): 101812, 2025 - Kobayashi S, Nakamura Y, Hashimoto T, Bando H, Oki E, Karasaki T, Horinouchi H, Ozaki Y, Iwata H, Kato T, Miyake H, Ohba A, Ikeda M, Chiyoda T, Hasegawa K, Fujisawa T, Matsuura K, Namikawa K, Yajima S, Yoshino T, Hasegawa K.
Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.
Int J Clin Oncol. 30(4): 605-654, 2025 - Takahashi Y, Fujiwara H, Yamamoto K, Yamaguchi S, Nagao S, Takano M, Miyamoto M, Hasegawa K, Miwa M, Yasuoka T, Yamashita S, Hirakawa T, Nagai T, Hamada Y, Uno M, Mori-Uchino M, Ohwada M, Mitsuhashi A, Satoh T, Fujiwara K, Suzuki M; GOTIC-VTE Trial Investigators.
Incidence and risk factors for venous thromboembolism in gynecological cancer: the GOTIC-VTE trial.
J Thromb Thrombolysis. 58(2): 299-308, 2025 - Eskander R, Lee JY, Mirza M, Lorusso D, Mackay H, Ray-Coquard I, Oaknin A, Gonzalez-Martin A, Hasegawa K, Corr B, Wu X, Leary A, Hu T, Dutta L, Okpara C, McKenzie J, Makker V.
TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians’ Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy.
J Natl Compr Canc Netw. 23(3.5): TIP25-243, 2025 - Hayato S, Hamuro L, Shimizu T, Yonemori K, Nishio S, Yunokawa M, Yoshida T, Nishio M, Matsumoto K, Takehara K, Hasegawa K, Kozuki T, Hirashima Y, Kato H, Miura T, Nomoto M, Zhao Y, Zhu L, Yasuda S.
Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors.
J Clin Pharmacol. 65(6): 751-762, 2025 - Eskander RN, Corr B, Cibula D, Tan DSP, Cloven N, Guerra E, Hasegawa K, Myers T, You B, Makker V, Zagouri F, Gien LT, Bartoletti M, Mallen A, Woelber L, Mocci S, Komatsubara K, Ma L, Colombo N.
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician’s choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT -en26/APGOT-EN2).
Int J Gynecol Cancer. 102654. doi: 10.1016/j.ijgc.2025.102654, 2025 - Tamura Y, Kondo N, Tsukada F, Tanaka M, Kono M, Hasegawa K, Muraoka N, Shigematsu K, Matsumoto R, Ogihara Y, Ikeda N, Shoji M, Kumamaru H, Miyata H, Miyata T.
Real-World Safety and Effectiveness of Rivaroxaban in Cancer-Associated Venous Thromboembolism (PRIMECAST) - A Prospective Multicenter Study.
Circ J. doi: 10.1253/circj.CJ-25-0541, 2025 - Miyama Y, Uranishi K, Hirasaki M, Tonooka A, Kawakami F, Mikami Y, Kiyokawa T, Kajiwara H, Shiraishi J, Kudo E, Ito K, Higashi M, Minamiguchi S, Okazaki N, Kondo Y, Shimada T, Maeda Y, Yasuhara Y, Kawano Y, Kawasaki Y, Hasegawa K, Yasuda M.
Multi-institutional study of mesonephric-like adenocarcinoma: its clinicopathological characteristics and histogenetic association with ectopic endometrium.
Virchows Arch. doi: 10.1007/s00428-025-04286-0, 2025 - Yamamoto Y, Osawa I, Takahashi M, Hasegawa K, Yasuda M.
Ovarian Sertoli-Leydig Tumour in a Postmenopausal Female With Virilisation: Magnetic Resonance Imaging Findings.
Cureus. 17(6): e85965, 2025 - Inoue K, Koyama M, Yasuda M, Hasegawa K, Kozawa E.
Fallopian Tube Carcinosarcoma With Intrauterine Fluid Accumulation: MRI Findings, Diagnostic Challenges, and Long-Term Survival.
Cureus. 17(7): e87857, 2025. - Mizoguchi C, Nishikawa T, Yoshida H, Yasuda M, Kato T, Hasegawa K, Yonemori K.
HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma.
J Gynecol Oncol. 36(1): e14, 2025 - Yoshida H, Li J, Inui H, Rokugawa K, Fujiwara K.
RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer.
Sci Rep. 15(1): 38089, 2025 - Takahashi K, Yoshida S, Aoki S, Tanaka S, Kawashima A, Kajiwara K, Kato N, Matsui H, Serizawa M, Tsuji S, Yamamoto T, Kinjo T, Nakamura N, Sagawa M, Sato M, Abe E, Nakanishi S, Fujimoto Y, Takahashi S, Sasaki H, Mukai Y, Hara S, Fukuta K, Kikuchi N, Hara E, Shiga T, Horiuchi C, Sado T, Matsubara Y, Akabane K, Harada A, Nagase H, Maeda K, Katagiri H, Sasahara J, Sugii H, Tamaru S, Waratani M, Tsukahara S, Shibukawa S, Kiyama T, Kasuga Y, Egawa M, Sato H, Tamamura C, Suemitsu T, Okamoto A, Samura O.
Perinatal outcomes in RhD-negative pregnant women in Japan.
Sci Rep. 15(1): 9921, 2025 - Fujiwara K, Nagao S, Tan D, Hasegawa K.
Intraperitoneal chemotherapy is now back for ovarian cancer.
Int J Clin Oncol. 30(3): 427-433, 2025 - Yamashita Y, Shirato N, Ishii T, Izumi M, Ichizuka K, Tominaga M, Komatsu R, Kondo T, Wada S, Sago H, Ito Y, Samura O, Suzumori N, Sawai H, Katagiri Y, Maeda Y, Morisaki H, Namba A, Kamei Y, Yotsumoto J, Hasegawa Y, Miura K, Nakayama S, Kawaguchi S, Hamanoue H, Mimura K, Matsubara Y, Okamoto Y, Fujiwara A, Maeda K, Watanabe T, Ida A, Hayakawa H, Goto K, Sekizawa A.
Perinatal outcomes of fetal CNVs detected by genome-wide non-invasive prenatal testing in Japan.
J Hum Genet. doi: 10.1038/s10038-025-01409-y. Online ahead of print., 2025 - Sasagasako N, Aoki-Kamiya C, Tada Y, Miyake T, Maezawa T, Kawabata H, Kawasaki K, Takamura M, Okunomiya A, Yoshimatsu J.
The current status of preconception counseling for female cancer survivors on cardiovascular complications in pregnancy: A questionnaire survey to doctors and survivors.
J Obstet Gynaecol Res. 2025 Mar;51(3):e16252. doi: 10.1111/jog.16252.
- Takekuma M, Nishio S, Yamaguchi S, Yunokawa M, Nishio H, Nishino K, Kurosaki A, Minobe S, Villacampa G, Oaknin A, Okamoto A.
Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc.
J Gynecol Oncol. 36(6): e116, 2025 - Yazaki S, Hori M, Aiba H, Momozawa Y, Yoshida M, Shiino S, Harano K, Yamauchi C, Yamanaka T, Miwa M, Matsuda K, Kawai Y, Kobayashi-Kato M, Kitagawa M, Saito M, Nakagomi H, Tachibana K, Sakamoto I, Takahashi K, Asami Y, Katanoda K, Kuchiba A, Yoshida H, Ishikawa M, Shimoi T, Sudo K, Shimizu C, Shimomura A, Murata T, Yamashita Y, Kogawa T, Fujiwara S, Saji H, Kato H, Miyagi E, Iwasaki Y, Aoi T, Takata S, Ogasawara A, Ohtake T, Fujimori K, Hirotsu Y, Nagashima M, Komatsu M, Hamamoto R, Hirata M, Yoshida T, Honda T, Hiranuma K, Matsuda M, Shimada Y, Sunami K, Noiri E, Omae Y, Matsumoto K, Okamoto A, Omata M, Watanabe T, Miyagi Y, Murakami Y, Tokunaga K, Hasegawa K, Kato T, Onishi T, Yamashita T, Naito Y, Suto A, Yonemori K, Kohno T, Shiraisihi K; BioBank Japan Project; NCBN Controls WGS Consortium.
Impact of germline variants on breast and ovarian cancer risk in Japanese women: an original cohort study and meta-analysis.
EBioMedicine. 116: 105758, 2025 - Masago K, Sasaki E, Fujita Y, Fujita S, Horio Y, Kuroda H, Ogasawara A, Tatsuno K, Aburatani H, Oda K, Hasegawa K, Matsushita H.
Identification of novel gene fusions in high-grade serous ovarian carcinoma: implications for tumorigenesis and targeted therapy.
Cancer Genet. 298-299: 159-168, 2025 - Yano M, Katoh T, Miyazawa M, Ogasawara A, Hasegawa K, Kobayashi E, Yasuda M.
Histone deacetylase 6 and programmed death ligand-1 expressions after neoadjuvant chemotherapy are upregulated in patients with ovarian high-grade serous carcinoma.
Sci Rep. 15(1): 19231, 2025 - Sato S, Miura T, Ogasawara A, Shintani D, Yamaguchi S, Inui H, Yoshinaga A, Nishiyama M, Tsugane M, Hasegawa K.
Evaluating the specific STAT3 inhibitor YHO-1701 in ovarian cancer cell lines and patient-derived cell models: efficacy, mechanisms, and therapeutic potential.
J Gynecol Oncol. 36(2): e24, 2025 - Yagishita S, Sato S, Shintani D, Nishikawa T, Ogasawara A, Yasuda M, Ishii H, Furuuchi K, Uenaka T, Yoshida H, Hasegawa K, Hamada A.
Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models.
Mol Cancer Ther. 24(11): 1789-1801, 2025 - Sato S, Yagishita S, Yoshida H, Shintani D, Ogasawara A, Nishikawa T, Yasuda M, Furuuchi K, Uenaka T, Hamada A, Hasegawa K.
Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, and therapeutic target profiling.
Neoplasia. 64: 101158, 2025 - Sato S, Shintani D, Kaneda Y, Nakamura R, Katoh T, Yano M, Hanaoka M, Yagishita S, Yasuda M, Nagata M, Hasegawa K.
Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma.
Int J Clin Oncol. 30(4): 805-813, 2025 - Yamaguchi T, Takamura M, Tochigi H, Mizuno Y, Mizuno Y, Sato T, Tamaru S, Kusama K, Tamura K, Kamei Y, Kajihara T.
Loss of miR-424 and miR-503 promotes decidualization of human endometrial stromal cells by increasing SCARA5 expression.
Med Mol Morphol. 58(4): 270-280, 2025 - Yamagata K, Mizuno Y, Mizuno Y, Tamaru S, Kajihara T.
Androgens modulate endometrial function.
Med Mol Morphol. 58(2): 93-99, 2025 - Kusama K, Ashihara M, Okita M, Yoshida K, Suzuki M, Suzuki K, Hosokawa R, Yoshie M, Kojima J, Mizuno Y, Ono M, Nishi H, Kajihara T, Tamura K.
Role of Transcription Factor, LIM Homeobox 9 (LHX9) in Inflammatory Response by PGE2 and Thrombin in SERPINA1-Silencing Endometrial Stromal Cells.
Mol Reprod Dev. 92(8): e70046, 2025
Jwa SC, Takano N, Tamaru S, Kijima S, Uesato T, Matsubara K, Tanaka K, Doi K, Sameshima H, Iriyama T, Fukushima K, Hirata Y, Fujii T, Ishiwata I, Kamei Y, Seki H; Japan Association of Obstetricians and Gynecologists Telemedicine Proof-of-Concept Home Blood Pressure Research Group.
Seasonal variation in home blood pressure during pregnancy and frequency of hypertensive disorders of pregnancy: a multicenter prospective study of home blood pressure measurements in pregnant women using information technology.
Hypertens Res. 48(1): 110-120, 2025
邦 文
- 上村のぞみ、左 勝則、佐藤麻弥、丸茂雄太、齋藤良平、高村将司、難波 聡、梶原 健、亀井良政
大学病院リプロダクションセンターにおける動画を用いた患者説明の妥当性評価
埼玉産科婦人科学会雑誌55(1): 1-8, 2025 - 鷹野夏子、田丸俊輔、板倉桜子、鈴木裕之、高村将司、梶原 健、亀井良政
妊娠高血圧症候群が常位胎盤早期剥離の転帰に与える影響の検討
関東連合産科婦人科学会誌62(4): 383-388, 2025
論文総説
英 文
- Ogasawara A, Hasegawa K.
Recent advances in immunotherapy for cervical cancer.
Int J Clin Oncol. 30(3): 434-448, 2025
邦 文
- 亀井良政
周産期医療における最近の進歩 遠隔医療から遺伝診療まで
栃木県産婦人科医報51: 73-75, 2025 - 亀井良政
【分娩管理のABC-入院から産褥まで】器械分娩の選択 鉗子分娩
臨床婦人科産科79(2): 244-251, 2025 - 亀井良政
【実践! 無痛分娩-安全な分娩管理のポイント】自己調節硬膜外鎮痛法（PCEA）
臨床婦人科産科79(12): 1113-1117, 2025 - 梶原 健
【エキスパートに聞く!不妊治療施設における指針と工夫】一般不妊治療 一般不妊治療における検査スケジュールと指針
産科と婦人科92(7): 717-721, 2025 - 小澤栄人、馬場康貴、長谷川幸清、安田政実
【エキスパートをめざす産婦人科の画像診断 Case-based review】子宮体部 子宮体部腺癌の新たなサブタイプ
画像診断45(2): 170-171, 2025 - 田丸俊輔
【産婦人科にかかわる医用技術の新たな進歩I】情報管理に関する新技術の導入 遠隔医療・オンライン診療の向こうにある新たな診療形態
産婦人科の実際74(1): 47-51, 2025 - 田丸俊輔
健康相談Q＆A 「子どもの保育園でリンゴ病が流行している。」
月刊「すこやかファミリー」 2025年3月号: 31, 2025 - 田丸俊輔
2024年度 埼玉県における周産期医療情報ネットワーク体制の構築について
埼玉県産婦人科医会報52: 33, 2025 - 難波 聡
【産婦人科医が知っておきたい 女性アスリートの生涯サポート】女性アスリートの骨健康と骨粗鬆症予防
産婦人科の実際74(8): 757-762, 2025 - 黒崎 亮
【新規抗悪性腫瘍薬の開発】免疫チェックポイント阻害薬と分子標的薬の併用 免疫チェックポイント阻害薬+PARP阻害薬
腫瘍内科35(1): 48-53, 2025 - 宮﨑加寿子
【イラスト・写真でコツがわかる!産婦人科小手術&低侵襲手術】(第3章)低侵襲手術の実際とコツ 腟 子宮筋腫・骨盤臓器脱など/腟式子宮全摘術+腟壁形成術
産科と婦人科92(Suppl): 194-199, 2025 - 小笠原仁子、佐藤正易、長谷川幸清
【産婦人科領域のトランスレーショナルリサーチの展開-若手医師への研究のススメ-】婦人科腫瘍 婦人科がんの新規免疫治療法の開発の現状
産科と婦人科92(3): 245-251, 2025 - 重松幸佑、濱川和音、長谷川幸清
【「ADC時代」の到来-チソツマブ ベドチン,そしてその先へ】婦人科悪性腫瘍に対するADCの臨床開発と今後の展望
産婦人科の実際74(7): 687-691, 2025 - 齋藤良平、高村将司、梶原 健
【ARTの周産期予後への影響】妊娠成立時の背景因子と周産期予後 胚移植時の子宮内膜厚と周産期合併症
臨床婦人科産科79(6): 522-528, 2025
